Alphamab Oncology (HKG:9966) said the Center for Drug Evaluation of China's National Medical Products Administration approved the new investigational drug application for its new anti-tumor drug after the phase I/II clinical trial, according to a Tuesday filing with the Hong Kong bourse.
JSKN033-102 is a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate and PD-L1 immune checkpoint inhibitor, the filing added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。